Eli Lilly’s Bold Move: A Lifeline for Gene Therapy’s Bleak Horizon?
Sangamo Therapeutics and Eli Lilly inked an $18 million deal to advance treatments for central nervous system diseases using Sangamo's STAC-BBB technology. The STAC-BBB capsid can effectively penetrate the blood-brain…